<DOC>
	<DOCNO>NCT00724061</DOCNO>
	<brief_summary>RATIONALE : PEG-interferon alfa-2b may interfere growth cancer cell slow growth mycosis fungoides/Sezary syndrome . Ultraviolet light therapy use drug , psoralen , absorb cancer cell . The drug become active exposed ultraviolet light . When drug active , cancer cell kill . Giving PEG-interferon alfa-2b together ultraviolet light therapy may kill cancer cell . PURPOSE : This pilot study dose-escalating pegylated IFN-α-2b PUVA NB-UVB . The purpose study side effect best dose PEG-interferon alfa-2b give together ultraviolet light therapy patient stage IB , stage II , stage III , stage IVA mycosis fungoides/Sezary syndrome ( CTCL ) .</brief_summary>
	<brief_title>Study Pegylated Interferon-Alfa 2b Combination With PUVA Therapy In CTCL</brief_title>
	<detailed_description>Patients receive PEG-interferon alfa-2b subcutaneously weekly 12 month absence disease progression unacceptable toxicity . Patients also receive UV light therapy ( either PUVA NB-UVB ) . Health-related quality life assess periodically use FACT-BRM , FACT-G , FACT-CTCL questionnaire . After completion study therapy , patient follow 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Ficusin</mesh_term>
	<mesh_term>Amotosalen</mesh_term>
	<mesh_term>Furocoumarins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm mycosis fungoides/Sezary syndrome Stage IBIVA disease Erythrodermic disease allow Measurable disease One indicatory lesion must designate prior study entry PATIENT CHARACTERISTICS : ECOG/WHO performance status 01 Life expectancy ≥ 3 month Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 75,000/mm³ WBC ≥ 3,000/mm³ Serum creatinine ≤ 2.0 mg/dL Total serum bilirubin ≤ 2.2 mg/dL Serum AST ALT ≤ 2 time upper limit normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Patients must disease free prior malignancy ≥ 5 year except currently treat squamous cell basal cell carcinoma skin , carcinoma situ cervix , surgically remove melanoma situ skin ( stage 0 ) , histologically confirm free margin excision No history seizure disorder severe heart disease No acute infection Diagnosed depression allow receive appropriate care depression PRIOR CONCURRENT THERAPY : No prior psoralens ultraviolet light A interferon alfa therapy More 4 week since prior topical therapy , systemic chemotherapy , biologic therapy More 4 week since prior surgery fully recover At least 1 week since prior antibiotic No concurrent standard investigational topical systemic antipsoriatic anticancer therapy include radiation , steroid , retinoids , nitrogen mustard , thalidomide , investigational agent No concurrent topical agent except emollient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
</DOC>